Breast Cancer Chemotherapy & Targeted Therapy Welfare Fund

Home / CSR / Breast Cancer Chemotherapy & Targeted Therapy Welfare Fund

Breast cancer is the most common type of cancer found in Malaysia. Around 5,000 Malaysian women are diagnosed with breast cancer every year, most of them aged between 30 and 60 years, and nearly half of those affected are under 50-years of age.

Chemotherapy is a treatment for breast cancer using anti-cancer (also called cytotoxic) drugs. The aim is to stop cancer cells from continuing to divide uncontrollably. Cancer cells grow by dividing in a disorderly and uncontrolled way. Chemotherapy gets in the form of their ability to share and grow. Different chemotherapy drugs work in different ways and affect the cancer cells to varying phases of their growth. This is why a combination of drugs is often used.

The cost of cancer treatment has been rising in recent year, making them unaffordable for low-income patients. It is difficult for patients who are having financial challenged to start their treatment due to the cost. For others, affording the cost of follow-up care can be a problem after their first treatment. The rising cost may cause some patients to skip or delay their treatment and put their chance of survival in jeopardy.

Under normal circumstances, the cost of chemotherapy treatment can reach up to RM4,000 – RM6,000 per cycle, and patients require 4 – 8 cycles of treatment. Under the Breast Cancer Chemotherapy Welfare Fund program, patients are required to pay about 10% of the charges. Beacon Hospital will subsidize the balance. This CSR program is intended to support the patient’s chemotherapy treatment for pre-selected chemotherapy protocols.

Drugs as per chemotherapy protocol

Day-care charges & consumables

Pre-treatment blood test

Take home medication

Chemotherapy drugs

Pre medication

Repeat blood test (If needed)

Other medications (If needed)

Open to Malaysian citizens who are diagnosed with early stage breast cancer.

Patients who are low income, financially challenged, exhausted their finances or insufficient insurance coverage.

Once the treatment plan is established, the attending oncologist will then refer the case to Beacon’s CSR office for financial assessment and eligibility.

Includes

Drugs as per chemotherapy protocol

Day-care charges & consumables

Pre-treatment blood test

Take home medication

Chemotherapy drugs

Pre medication

Does not include

Repeat blood test (If needed)

Other medications (If needed)

Eligibility

Open to Malaysian citizens who are diagnosed with early stage breast cancer.

Patients who are low income, financially challenged, exhausted their finances or insufficient insurance coverage.

Once the treatment plan is established, the attending oncologist will then refer the case to Beacon’s CSR office for financial assessment and eligibility.

Breast cancer is the most common cancer in women worldwide. The management of breast cancer is complex and is usually customized specifically for individual patients. 1 in 5 breast cancer patients is tested positive for Human Epidermal growth factor Receptor 2 (HER2). HER2 is a protein in the body that promotes the growth of cancer cells aggressively. For breast cancer patients who are HER2 positive, doctors often prescribe a drug called Trastuzumab alongside other treatments such as surgery, chemotherapy & radiotherapy to enhance the outcome of the treatment. This treatment, however, is very costly, and many patients could not afford to pay for it. As a result, some patients choose to go for unproven traditional treatments, which might cause bad outcome and recurrences.

The Targeted Therapy Welfare Fund for Breast Cancer is a corporate social responsibility (CSR) program initiated by Beacon Hospital and Roche Malaysia. The objective of this program is to reduce the financial burden of breast cancer patients by enabling them to gain access to targeted therapy (Trastuzumab). Under this program, eligible breast cancer patients are given access to this treatment at a subsidized rate. Patients are only required to pay RM2,500 per cycle for Trastuzumab treatment which is a fraction of the normal charges.

Targeted therapy medicine (Trastuzumab) * subcutaneous

Day-care charges / Drug preparation / Medical consumables

Nursing charges / Monitoring equipment

Doctor’s fee (RM150 per cycle only)

Lab tests (if needed)

Additional medication (if required)

Hospitalization/ Critical care (if required)

This Welfare Fund is open to Malaysian citizens only.

This Welfare Fund is for the patients who are low income, financially challenged, exhausted their finances or insufficient insurance coverage.

Breast cancer patients seeking adjuvant targeted therapy (Trastuzumab) as prescribed by the attending oncologist in Beacon Hospital.

Patients are diagnosed with early stage breast cancer.

Non-palliative and/or metastatic cases.

Includes

Targeted therapy medicine (Trastuzumab) * subcutaneous

Day-care charges / Drug preparation / Medical consumables

Nursing charges / Monitoring equipment

Does not include

Doctor’s fee (RM150 per cycle only)

Lab tests (if needed)

Additional medication (if required)

Hospitalization/ Critical care (if required)

Eligibility

This Welfare Fund is open to Malaysian citizens only.

This Welfare Fund is for the patients who are low income, financially challenged, exhausted their finances or insufficient insurance coverage.

Breast cancer patients seeking adjuvant targeted therapy (Trastuzumab) as prescribed by the attending oncologist in Beacon Hospital.

Patients are diagnosed with early stage breast cancer.

Non-palliative and/or metastatic cases.

CSR Number Update, November 2024, Beacon Hospital

Application Overview

Patients are required to consult oncologist as an outpatient (consultation charges apply) in Beacon Hospital.
The attending oncologist will then refer the case to Beacon’s CSR office for financial assessment and eligibility.
It will take approximately 1 – 2 working days to process the application.
Once the application is approved, the patient will be provided with a guarantee letter, which will enable the patient to get the treatment done at the agreed subsidized cost.

Terms & Conditions

This program is open to Malaysian citizens only.
This program is applicable to low income patients who are diagnosed with early stage breast cancer.
Applicants are required to fill up application form and submit with supporting documents to CSR department for assessment and approval.
Beacon Hospital Sdn Bhd reserves the rights to amend the terms & conditions anytime without prior notice.

Frequently Asked Questions

1. How can I enroll myself into this program?

Interested patients are to first consult an oncologist at Beacon Hospital to establish the best treatment plan. If the attending doctor prescribes chemotherapy as part of the treatment plan, patients will then be guided further to apply for this welfare fund. Simply fill in the form below.

2. How long will it take for my application to be processed?

All applications will be processed within 1 – 2 working days upon submission of complete documents. The decision may be delayed if the supporting documents are not complete. However, instant approval is allowed for special cases.

3. How much financial aid can I get?

The amount of welfare aid approved for each case is different. Various parameters, including treatment affordability, socio-economic status and past medical expenditure, are considered in processing your application, and will be used as the basis to determine how much aid you will be awarded.

4. I am not from Klang Valley and therefore cannot submit the required documents on time. Can I fax/mail/email the documents?

Yes. You may email to csr@beaconhospital.com.my or fax to 03 – 7786 0990. Kindly follow up with our CSR officers after faxing/mailing/emailing the documents to ensure that we have received them.